Johnson, M., Kumar, P., Molina, J., Rizzardini, G., Cahn, P., Bickel, M., . . . Greaves, W. (2019). Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr.
Citação norma ChicagoJohnson, Margaret, et al. "Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial." J Acquir Immune Defic Syndr 2019.
Citação norma MLAJohnson, Margaret, et al. "Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial." J Acquir Immune Defic Syndr 2019.